Jorgelindo da Veiga Moreira

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 6

Top Topics

Squamous Cell Carcinoma

Saccharomyces Cerevisiae

Mild Cognitive Impairment

Monoclonal Antibody

Top Venues

Scientific reports

This page only lists publications with an associated author ORCID identifier.

Publications

Jorgelindo da Veiga Moreira, Nancy Nleme, Laurent Schwartz, Kim Leclerc-Desaulniers, Euridice Carmona, Anne-Marie Mes-Masson, Mario Jolicoeur
Methylene Blue Metabolic Therapy Restrains In Vivo Ovarian Tumor Growth. Cancers 16 (2) (2024)
Jorgelindo da Veiga Moreira, Nancy Nleme, Laurent Schwartz, Kim Leclerc-Desaulniers, Euridice Carmona, Anne-Marie Mes-Masson, Mario Jolicoeur
Methylene Blue Metabolic Therapy Restrains In Vivo Ovarian Tumor Growth. Cancers 16 (2) (2024)
Jorgelindo da Veiga Moreira, Lenny De Staercke, Pablo César Martínez-Basilio, Sandrine Gauthier-Thibodeau, Léa Montégut, Laurent Schwartz, Mario Jolicoeur
Hyperosmolarity Triggers the Warburg Effect in Chinese Hamster Ovary Cells and Reveals a Reduced Mitochondria Horsepower. Metabolites 11 (6) (2021)
Laurent Schwartz, Sabine Peres, Mario Jolicoeur, Jorgelindo da Veiga Moreira
Cancer and Alzheimer's disease: intracellular pH scales the metabolic disorders. Biogerontology 21 (6) (2020)
Léa Montégut, Pablo César Martínez-Basilio, Jorgelindo da Veiga Moreira, Laurent Schwartz, Mario Jolicoeur
Combining lipoic acid to methylene blue reduces the Warburg effect in CHO cells: From TCA cycle activation to enhancing monoclonal antibody production. PloS one 15 (4) (2020)
Jorgelindo da Veiga Moreira, Minoo Hamraz, Mohammad Abolhassani, Laurent Schwartz, Mario Jolicœur, Sabine Peres
Metabolic therapies inhibit tumor growth in vivo and in silico. Scientific reports 9 (1) (2019)